Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing

References

• Bjornsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015 Mar;89(3):327–334.
   PubMed Web of Science ®Google Scholar
• Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010 Dec;52(6):2065–2076.
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y, et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol. 2012 Aug 20;25(8):1616–1632.
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Chan K, Silber PM. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact. 2004 Nov 1;150(1):97–114.
   PubMed Web of Science ®Google Scholar
• Park BK, Laverty H, Srivastava A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact. 2011 Jun 30;192(1–2):30–36.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):837–854.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Lahoz A, Gombau L, et al. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des. 2010 Jun;16(17):1963–1977.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Tolosa L, Conde I, et al. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1553–1568.
   PubMed Web of Science ®Google Scholar
• Donato MT, Jover R, Gomez-Lechon MJ. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab. 2013 Nov;14(9):946–968.
   PubMed Web of Science ®Google Scholar
• Godoy P, Hewitt NJ, Albrecht U, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013 Aug;87(8):1315–1530.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Donato MT, Castell JV, et al. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab. 2004 Oct;5(5):443–462.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39(1):159–234.
   PubMed Web of Science ®Google Scholar
• Schoonen WG, Stevenson JC, Westerink WM, et al. Cytotoxic effects of 109 reference compounds on rat H4IIE and human HepG2 hepatocytes. III: mechanistic assays on oxygen consumption with MitoXpress and NAD(P)H production with Alamar Blue. Toxicol In Vitro. 2012 Apr;26(3):511–525.
   PubMed Web of Science ®Google Scholar
• Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003 Aug;31(8):1035–1042.
   PubMed Web of Science ®Google Scholar
• Ilan Y, Saito H, Thummala NR, et al. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis. 1999;19(1):49–59.
   PubMed Web of Science ®Google Scholar
• Ferry N, Duplessis O, Houssin D, et al. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA. 1991 Oct 1;88(19):8377–8381.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Emerman M. Retroviral infection of non-dividing cells: old and new perspectives. Virology. 2006 Jan 5;344(1):88–93.
   PubMed Web of Science ®Google Scholar
• Barcelo S, Mace K, Pfeifer AM, et al. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f]quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. Mutat Res. 1998 Jun 18;402(1–2):111–120.
   PubMed Web of Science ®Google Scholar
• Bort R, Mace K, Boobis A, et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787–796.
   PubMed Web of Science ®Google Scholar
• Chu CC, Pan KL, Yao HT, et al. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. Biotechnol Bioeng. 2011 Dec;108(12):2932–2940.
   PubMed Web of Science ®Google Scholar
• Goldring CE, Kitteringham NR, Jenkins R, et al. Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. Am J Physiol Cell Physiol. 2006 Jan;290(1):C104–C115.
   Google Scholar
• Gustafsson F, Foster AJ, Sarda S, et al. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci. 2014 Jan;137(1):189–211.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol. 1995;35:369–390.
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Castell JV, et al. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008 Jan;9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Donato MT, Tolosa L, Gomez-Lechon MJ. Culture and functional characterization of human hepatoma HepG2 cells. Methods Mol Biol. 2015;1250:77–93.
   PubMedGoogle Scholar
• Jiang J, Briede JJ, Jennen DG, et al. Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139–150.
   PubMed Web of Science ®Google Scholar
• Frecha C, Szecsi J, Cosset FL, et al. Strategies for targeting lentiviral vectors. Curr Gene Ther. 2008 Dec;8(6):449–460.
   PubMed Web of Science ®Google Scholar
• Liao W, Ning G. Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA. Biochem Biophys Res Commun. 2006 Jun 2;344(2):478–483.
   PubMed Web of Science ®Google Scholar
• Nash KL, Jamil B, Maguire AJ, et al. Hepatocyte-specific gene expression from integrated lentiviral vectors. J Gene Med. 2004 Sep;6(9):974–983.
   PubMed Web of Science ®Google Scholar
• Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA. 1996 Mar 19;93(6):2348–2352.
   PubMed Web of Science ®Google Scholar
• Lackner A, Kreidl E, Peter-Vorosmarty B, et al. Stable protein expression in mammalian cells using baculoviruses. Methods Mol Biol. 2012;801:75–92.
   PubMedGoogle Scholar
• Matilainen H, Rinne J, Gilbert L, et al. Baculovirus entry into human hepatoma cells. J Virol. 2005 Dec;79(24):15452–15459.
   PubMed Web of Science ®Google Scholar
• Xuan J, Chen S, Ning B, et al. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact. 2016;255:63–73.
   PubMed Web of Science ®Google Scholar
• Yoshitomi S, Ikemoto K, Takahashi J, et al. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001 Jun;15(3):245–256.
   PubMed Web of Science ®Google Scholar
• Delescluse C, Ledirac N, Li R, et al. Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells. Biochem Pharmacol. 2001 Feb 15;61(4):399–407.
   PubMed Web of Science ®Google Scholar
• Zhu-Ge J, Ye S, Yu YN. [Establishment of a HepG2 cell line stably expressing human cytochrome P450 1A2 and its metabolic activity]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2003 Oct;32(5):403–406.
   PubMedGoogle Scholar
• Sato W, Suzuki H, Sasaki T, et al. Construction of a system that simultaneously evaluates CYP1A1 and CYP1A2 induction in a stable human-derived cell line using a dual reporter plasmid. Drug Metab Pharmacokinet. 2010;25(2):180–189.
   PubMed Web of Science ®Google Scholar
• Zhuge J, Luo Y, Yu YN. Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line. World J Gastroenterol. 2003 Dec;9(12):2732–2736.
   PubMed Web of Science ®Google Scholar
• Wu D, Cederbaum AI. Removal of glutathione produces apoptosis and necrosis in HepG2 cells overexpressing CYP2E1. Alcohol Clin Exp Res. 2001 Apr;25(4):619–628.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rashba-Step J, Cederbaum AI. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry. 1993 Jul 13;32(27):6928–6937.
   PubMed Web of Science ®Google Scholar
• Holownia A, Braszko JJ. Acetaminophen alters microsomal ryanodine Ca2+ channel in HepG2 cells overexpressing CYP2E1. Biochem Pharmacol. 2004 Aug 1;68(3):513–521.
   PubMed Web of Science ®Google Scholar
• Ogg MS, Gray TJ, Gibson GG. Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur J Drug Metab Pharmacokinet. 1997 Oct–Dec;22(4):311–313.
   PubMed Web of Science ®Google Scholar
• Ogg MS, Williams JM, Tarbit M, et al. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica. 1999 Mar;29(3):269–279.
   PubMed Web of Science ®Google Scholar
• Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res. 2003 Jun;27(6):981–988.
   PubMed Web of Science ®Google Scholar
• Feierman DE, Melnikov Z, Zhang J. The paradoxical effect of acetaminophen on CYP3A4 activity and content in transfected HepG2 cells. Arch Biochem Biophys. 2002 Feb 1;398(1):109–117.
   PubMed Web of Science ®Google Scholar
• Holownia A, Braszko JJ. Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4. Biochem Pharmacol. 2004 Mar 15;67(6):1057–1064.
   PubMed Web of Science ®Google Scholar
• Araki N, Tsuruoka S, Wang N, et al. Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity. Xenobiotica. 2008 Nov;38(11):1355–1364.
   PubMed Web of Science ®Google Scholar
• Frederick DM, Jacinto EY, Patel NN, et al. Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells. Toxicol In Vitro. 2011 Dec;25(8):2113–2119.
   PubMed Web of Science ®Google Scholar
• Zahno A, Brecht K, Morand R, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol. 2011 Feb 1;81(3):432–441.
   PubMed Web of Science ®Google Scholar
• Zahno A, Bouitbir J, Maseneni S, et al. Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. Free Radic Biol Med. 2013 Dec;65:208–216.
   PubMed Web of Science ®Google Scholar
• Huang L, Zou S, Deng J, et al. Development of an optimized cytotoxicity assay system for CYP3A4-mediated metabolic activation via modified piggyBac transposition. Toxicol In Vitro. 2016;32:132–137.
   PubMed Web of Science ®Google Scholar
• Kuang Z, Huang Z, Li Y, et al. Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells. Mol Med Rep. 2015 Apr;11(4):2868–2874.
   PubMed Web of Science ®Google Scholar
• Shou M, Korzekwa KR, Krausz KW, et al. Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450. Cancer Lett. 1994 Aug 15;83(1–2):305–313.
   PubMed Web of Science ®Google Scholar
• Thornton-Manning JR, Ruangyuttikarn W, Gonzalez FJ, et al. Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s. Biochem Biophys Res Commun. 1991 Nov 27;181(1):100–107.
   PubMed Web of Science ®Google Scholar
• Wickham TJ. Targeting adenovirus. Gene Ther. 2000 Jan;7(2):110–114.
   PubMed Web of Science ®Google Scholar
• Castell JV, Hernandez D, Gomez-Foix AM, et al. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther. 1997 May;4(5):455–464.
   PubMed Web of Science ®Google Scholar
• Becker TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43(Pt A):161–189.
   PubMed Web of Science ®Google Scholar
• Vetrini F, Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses. 2010 Sep;2(9):1886–1917.
   PubMed Web of Science ®Google Scholar
• McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988 Apr;163(2):614–617.
   PubMed Web of Science ®Google Scholar
• Aoyama K, Yoshinari K, Kim HJ, et al. Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. Drug Metab Pharmacokinet. 2009;24(3):209–217.
   PubMed Web of Science ®Google Scholar
• Bai J, Cederbaum AI. Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity. Mol Cell Biochem. 2004 Jul;262(1–2):165–176.
   PubMed Web of Science ®Google Scholar
• Tolosa L, Donato MT, Perez-Cataldo G, et al. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. Toxicol In Vitro. 2012 Dec;26(8):1272–1277.
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, et al. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch Toxicol. 2013 Jun;87(6):1115–1127.
   PubMed Web of Science ®Google Scholar
• Vignati L, Turlizzi E, Monaci S, et al. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology. 2005 Dec 15;216(2–3):154–167.
   PubMed Web of Science ®Google Scholar
• Hashizume T, Yoshitomi S, Asahi S, et al. Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488–497.
   PubMed Web of Science ®Google Scholar
• Lahoz A, Vila MR, Fabre M, et al. An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors. Toxicol In Vitro. 2013 Jun;27(4):1410–1415.
   PubMed Web of Science ®Google Scholar
• Hosomi H, Fukami T, Iwamura A, et al. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos. 2011 Aug;39(8):1388–1395.
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Hosomi H, Fukami T, et al. Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxicol In Vitro. 2009 Sep;23(6):1179–1187.
   PubMed Web of Science ®Google Scholar
• Hosomi H, Akai S, Minami K, et al. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro. 2010 Apr;24(3):1032–1038.
   PubMed Web of Science ®Google Scholar
• Iwamura A, Fukami T, Hosomi H, et al. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos. 2011 May;39(5):838–846.
   PubMed Web of Science ®Google Scholar
• Kwon SJ, Lee DW, Shah DA, et al. High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. Nat Commun. 2014;5:3739.
   PubMed Web of Science ®Google Scholar
• Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;196:369–405.
   PubMedGoogle Scholar
• Raucy JL, Lasker JM, Lieber CS, et al. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989 Jun;271(2):270–283.
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul;109(7):950–66; quiz 67.
   PubMed Web of Science ®Google Scholar
• Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol. 2008 May;24(3):287–297.
   PubMed Web of Science ®Google Scholar
• Sakatis MZ, Reese MJ, Harrell AW, et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem Res Toxicol. 2012 Oct 15;25(10):2067–2082.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Kalgutkar AS, Chen W. Practical approaches to resolving reactive metabolite liabilities in early discovery. Drug Metab Rev. 2015 Feb;47(1):56–70.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Didiuk MT. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem Biodivers. 2009 Nov;6(11):2115–2137.
   PubMed Web of Science ®Google Scholar
• Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform. 2015;7:4.
   PubMed Web of Science ®Google Scholar
• Obach RS, Kalgutkar AS, Soglia JR, et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol. 2008 Sep;21(9):1814–1822.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Pasanen M, Tolonen A, et al. Reactive metabolites in early drug development: predictive in vitro tools. Curr Med Chem. 2015;22(4):538–550.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao N, Liu T, et al. Effect of cytochrome b5 content on the activity of polymorphic CYP1A2, 2B6, and 2E1 in human liver microsomes. PLoS One. 2015 Jun 5;10(6):e0128547.
   Google Scholar
• Gan L, von Moltke LL, Trepanier LA, et al. Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. Drug Metab Dispos. 2009 Jan;37(1):90–96.
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Maiter D, Kirchheiner J, et al. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol. 2010 Dec;163(6):919–924.
   PubMed Web of Science ®Google Scholar
• Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012 Feb;44(1):107–115.
   PubMed Web of Science ®Google Scholar
• Liu F, Cai P, Metushi I, et al. Exploring an animal model of amodiaquine-induced liver injury in rats and mice. J Immunotoxicol. 2016 Sep;13(5):694–712.
   PubMed Web of Science ®Google Scholar
• Fasani RA, Livi CB, Choudhury DR, et al. The human toxome collaboratorium: a shared environment for multi-omic computational collaboration within a consortium. Front Pharmacol. 2015;6:322.
   PubMed Web of Science ®Google Scholar
• Leung L, Kalgutkar AS, Obach RS. Metabolic activation in drug-induced liver injury. Drug Metab Rev. 2012 Feb;44(1):18–33.
   PubMed Web of Science ®Google Scholar